Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refractory Leukemia
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)
Novartis
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Janssen Research & Development, LLC
Dana-Farber Cancer Institute
University of Chicago
Auron Therapeutics, Inc.
Biomea Fusion Inc.
Senti Biosciences
H. Lee Moffitt Cancer Center and Research Institute
Dana-Farber Cancer Institute
St. Jude Children's Research Hospital
Children's Oncology Group
Beth Israel Deaconess Medical Center
Polaris Group
Byondis B.V.
Dana-Farber Cancer Institute
University of Pennsylvania
Great Ormond Street Hospital for Children NHS Foundation Trust
M.D. Anderson Cancer Center
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Thomas Jefferson University
Dana-Farber Cancer Institute
University Health Network, Toronto
National Cancer Institute (NCI)
Baylor College of Medicine
Northwestern University
Northwestern University
OHSU Knight Cancer Institute
Sichuan Baili Pharmaceutical Co., Ltd.
University of Alabama at Birmingham
Baylor College of Medicine
City of Hope Medical Center
City of Hope Medical Center
National Cancer Institute (NCI)
Johns Hopkins All Children's Hospital
Cellectis S.A.
AbbVie
Chinese PLA General Hospital
Baylor College of Medicine
Foghorn Therapeutics Inc.
City of Hope Medical Center
Eli Lilly and Company
University of Pennsylvania
City of Hope Medical Center